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Autosomal recessive Pseudohypoaldosteronism Type I
(PHA-I, MIM#264350), is a rare disease with a severe
clinical phenotype [1,2] and generally no improvement
with age [3]. It results from mutations in the amiloride-
sensitive epithelial sodium channel causing mineralocor-
ticoid-resistant (ENaC), systemic salt wasting, and is
lethal without ongoing supra-physiological sodium sup-
plementation and management of hyperkalaemia [4,5].
Other manifestations of systemic PHA-I include
decreased sodium-dependant clearance of alveolar fluid
causing recurrent chest congestion, cough and wheeze,
but no airway infection by bacterial pathogens typifying
cystic fibrosis[6,7]; and skin rashes from inflammation
of sodium-blocked sweat glands [8] with recurrent Sta-
phylococcal skin infections described [9].
Our patient, now nearly four years old, presented as a
day 6 neonate with vomiting, apnoea and floppiness. She
was shocked and dehydrated with hyponatraemia, marked
hyperkalaemia with runs of ventricular tachycardia.
PHA-1 was diagnosed with high cortisol, renin and
aldosterone, normal 17-hydroxyprogesterone, inappro-
priately high spot urine sodium with low potassium, and
normal renal ultrasound. Diagnosis was genetically con-
firmed with the finding of two inherited, distinct, disease
causing mutations in the SCNNIA gene. Increased sweat
sodium confirmed systemic salt-wasting. Initial manage-
ment included a high-sodium, low-potassium formula
(Kindergen) supplemented with 22 mmol/Kg/day of ent-
eral sodium, the use of daily potassium binding resin
(Resonium), and trial of Fludrocortisone.
Requirement for daily large doses of sodium 16 mmol/
Kg/day, provided as a mix of sodium citrate and sodium
chloride, and daily Resonium continues. Significant oral
aversion remains an issue with good growth achieved on
calorie-concentrated Kindergen. Gastrostomy feeding
was changed to percutaneous jejunal continual feeding
due to persistent gastric emptying problems. Central
venous access established early has posed ongoing chal-
lenges, with intermittent Staphylococcal infections. Our
patient has also been hypertensive requiring medical
management from 6 months age. She has a recurrent
moist cough with past Haemophilus infection.
Minimising inpatient management is vital for estab-
lishing ‘normality’ and optimising development. The
need for frequent electrolyte monitoring and adjustment
of sodium intake is managed creatively between home
and hospital in close liaison with her paediatric endocri-
nologist and community-based supports. Clear emer-
gency management plans involving early symptom
recognition and rapid hospital-access are instituted to
manage salt-wasting episodes.
We shall discuss the challenges and pitfalls of mana-
ging this rare, life-threatening disease with sparse long-
term prognostic information, in the Australian health
care context.
Written informed consent was obtained from the par-
ent of the patient for publication of this abstract and
any accompanying images. A copy of the written consent
is available for review by the Editor of this journal.
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